|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma显示文摘Hepatocellular carcinoma (HCC) is the most common liver malignancy worldwide and a major cause of cancer-related mortality for which liver resection is an important curative-intent treatment option. However, many patients present with advanced disease and with underlying chronic liver disease and/or cirrhosis, limiting the proportion of patients who are surgical candidates. In addition, the development of recurrent or de novo cancers following surgical resection is common. These issues have led investigators to evaluate the benefit of neoadjuvant and adjuvant treatment strategies aimed at improving resectability rates and decreasing recurrence rates. While high-level evidence to guide treatment decision making is lacking, recent advances in locoregional and systemic therapies, including antiviral treatment and immunotherapy, raise the prospect of novel approaches that may improve the outcomes of patients with HCC. In this review, we evaluate the evidence for various neoadjuvant and adjuvant therapies and discuss opportunities for future clinical and translational research. | Clifford Akateh Sylvester M Black Lanla Conteh Eric D Miller Anne Noonan Eric Elliott Timothy M Pawlik Allan Tsung Jordan M Cloyd | 2019 | World Journal of Gastroenterology2019，25，28： | 16 |
| 2 | Duodenal adenocarcinoma: Advances in diagnosis and surgical management显示文摘Duodenal adenocarcinoma is a rare but aggressive malignancy. Given its rarity, previous studies have traditionally combined duodenal adenocarcinoma(DA) with either other periampullary cancers or small bowel adenocarcinomas, limiting the available data to guide treatment decisions. Nevertheless, management primarily involves complete surgical resection when technically feasible. Surgery may require pancreaticoduodenectomy or segmental duodenal resection; either are acceptable options as long as negative margins are achievable and an adequate lymphadenectomy can be performed. Adjuvant chemotherapy and radiation are important components of multi-modality treatment for patients at high risk of recurrence. Further research would benefit from multiinstitutional trials that do not combine DA with other periampullary or small bowel malignancies. The purpose of this article is to perform a comprehensive review of DA with special focus on the surgical management and principles. | Jordan M Cloyd Elizabeth George Brendan C Visser | 2016 | World Journal of Gastrointestinal Surgery2016，8，3： | 13 |
| 3 | Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management显示文摘Nonfunctional neuroendocrine tumors of the pancreas(NF-PNETs) are a heterogeneous group of neoplasms. Although rare, the incidence of NF-PNETs is increasing significantly. The classification of PNETs has evolved over the past decades and is now based on a proliferation grading system. While most NF-PNETs are slow growing, tumors with more aggressive biology may becomeincurable once they progress to unresectable metastatic disease. Tumors of higher grade can be suspected preoperatively based on the presence of calcifications, hypoenhancement on arterial phase computed tomography, positron emission technology avidity and lack of octreotide scan uptake. Surgery is the only curative treatment and is recommended for most patients for whom complete resection is possible. Liver-directed therapies(thermal ablation, transarterial embolization) can be useful in controlling unresectable hepatic metastatic disease. In the presence of unresectable progressive disease, somatostatin analogues, everolimus and sunitinib can prolong progression-free survival. This article provides a comprehensive review of NF-PNETs with special emphasis on recent advances in diagnosis and management. | Jordan M Cloyd George A Poultsides | 2015 | World Journal of Gastroenterology2015，21，32： | 11 |
| 4 | Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma显示文摘Intrahepatic cholangiocarcinoma(ICC)is the second most common primary liver malignancy and is increasing in incidence.Long-term outcomes are optimized when patients undergo margin-negative resection followed by adjuvant chemotherapy.Unfortunately,a significant proportion of patients present with locally advanced,unresectable disease.Furthermore,recurrence rates are high even among patients who undergo surgical resection.The delivery of systemic and/or liver-directed therapies prior to surgery may increase the proportion of patients who are eligible for surgery and reduce recurrence rates by prioritizing early systemic therapy for this aggressive cancer.Nevertheless,the available evidence for neoadjuvant therapy in ICC is currently limited yet recent advances in liver directed therapies,chemotherapy regimens,and targeted therapies have generated increasing interest its role.In this article,we review the rationale for,current evidence for,and ongoing research efforts in the use of neoadjuvant therapy for ICC. | Clifford Akateh Aslam M Ejaz Timothy Michael Pawlik Jordan M Cloyd | 2020 | World Journal of Hepatology2020，12，10： | 8 |
| 5 | Neoadjuvant chemotherapy for colorectal liver metastases:A contemporary review of the literature显示文摘Colorectal carcinoma(CRC)is one of the leading causes of cancer-related deaths worldwide,and up to 50%of patients with CRC develop colorectal liver metastases(CRLM).For these patients,surgical resection remains the only opportunity for cure and long-term survival.Over the past few decades,outcomes of patients with metastatic CRC have improved significantly due to advances in systemic therapy,as well as improvements in operative technique and perioperative care.Chemotherapy in the modern era of oxaliplatin-and irinotecancontaining regimens has been augmented by the introduction of targeted biologics and immunotherapeutic agents.The increasing efficacy of contemporary systemic therapies has led to an expansion in the proportion of patients eligible for curative-intent surgery.Consequently,the use of neoadjuvant strategies is becoming progressively more established.For patients with CRLM,the primary advantage of neoadjuvant chemotherapy(NCT)is the potential to down-stage metastatic disease in order to facilitate hepatic resection.On the other hand,the routine use of NCT for patients with resectable metastases remains controversial,especially given the potential risk of inducing chemotherapy-associated liver injury prior to hepatectomy.Current guidelines recommend upfront surgery in patients with initially resectable disease and low operative risk,reserving NCT for patients with borderline resectable or unresectable disease and high operative risk.Patients undergoing NCT require close monitoring for tumor response and conversion of CRLM to resectability.In light of the growing number of treatment options available to patients with metastatic CRC,it is generally agreed that these patients are best served at tertiary centers with an expert multidisciplinary team. | Marissa Guo Ning Jin Timothy Pawlik Jordan M Cloyd | 2021 | World Journal of Gastrointestinal Oncology2021，13，9： | 2 |
| 6 | Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research显示文摘Pancreatic ductal adenocarcinoma is an aggressive cancer with high recurrence rates following surgical resection.While adjuvant chemotherapy improves survival,a significant proportion of patients are unable to initiate or complete all intended therapy following pancreatectomy due to postoperative complications or poor performance status.The administration of chemotherapy prior to surgical resection is an alternative strategy that ensures its early and near universal delivery as well as improves margin-negative resection rates and potentially improves long-term survival outcomes.Neoadjuvant therapy is increasingly being recommended to patients with pancreatic ductal adenocarcinoma,however,patient-centered research on its use is lacking.In this review,we highlight opportunities to focus research efforts in the domains of patient preferences,patient-reported outcomes,patient experience,and survivorship.Novel research in these areas may identify relevant barriers and facilitators to the use of neoadjuvant therapy thereby increasing its utilization,improve shareddecision making for patients and providers,and optimize the experience of those undergoing neoadjuvant therapy. | Jordan M Cloyd Allan Tsung John Hays Celia E Wills John FP Bridges | 2020 | World Journal of Gastroenterology2020，26，4： | 2 |
| 7 | Out-of-hospital treatment of status epilepticus in children显示文摘 | Lowenstein DH Cloyd J | 2006 | Curr Opin Pediatr2006，18，3： | 1 |
| 8 | Using the double - cord packing technique of tissueretraction for making crown impressions 显示文摘 | Cloyd S Purl S | 1999 | Dent Today1999，18，1： | 1 |
| 9 | Outpatient laparoscopic lumbar diskectomy: description of technique and review of first 21 cases显示文摘 | OBENCHAIN TG CLOYD D | 1994 | Surgi Technolo lnt1994，2，： | 1 |
| 10 | En bloc resection for pri- mary and metastatic tumors of the spine: a systematic review of the lit- erature 显示文摘 | Cloyd JM Acosta FL Jr Policy MY | 2010 | Neurosurgery2010，67，2： | 1 |
| 11 | Therelationship between stress and the development of diabetic complications显示文摘 | Cloyd CE | 1991 | Diabetes Med1991，8，2： | 1 |
| 12 | Laparoscopic lumbar discectomy: description of transperitoneal and retroperitoneal techniques显示文摘 | Obenchain TG Cloyd D | 1996 | Neurosurg Clin N Am1996，7，1： | 1 |
| 13 | Clonazepam and pregnancy显示文摘 | Kriel RL Cloyd J | 1982 | Ann Neurol1982，11，5： | 1 |
| 14 | Status of the United States Air Force's More Electric Aircraft Initiative显示文摘 | CLOYD J S | 1998 | Aerospace and Electronic Systems Magazine1998，13，4： | 1 |
| 15 | En bloc resection of primary tumors of the cervical spine:report of two cases and systematic review of the literature显示文摘 | Cloyd JM Chou D Deviren V | | 0，，11： | 1 |
| 16 | A status of the united states air force's more electric aircraft initiative显示文摘 | Cloyd J S | 1998 | IEEE Aerospace and Electronic SystemsMagazine1998，13，4： | 1 |
| 17 | Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance and preference 显示文摘 | Cloyd JC Kriel RL Jones-Saete CM | 1992 | Pediatrics1992，120，41： | 1 |
| 18 | Epidemiologica land medical aspects of epilepsyin the elderly显示文摘 | Cloyd J Hauser W Towne A | 2006 | Epilepsy Res2006，68，1： | 1 |
| 19 | The effect of shareholder- level dividend taxes on stock prices:evidence from the rev- enue reconciliation act of 1993 显示文摘 | Ayers C Cloyd B Robinson R | 2002 | The Accounting Re- view2002，77，4： | 1 |
| 20 | Status of the united states air force's more electric aircraft initiative显示文摘 | | 1998 | Aerospace and Electronic Systems Magazine IEEE1998，13，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员